From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.
PROVIDENCE CANCER INSTITUTE – It is with deep sadness we announce the passing of Elsie Franz Finley who died Aug. 14, 2018. She was 97 years old.
Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other immunotherapies can be most beneficial to patients with this difficult-to-treat disease. At Providence Cancer Institute, four new studies of different immunotherapy approaches are now open to patients.
More than 161,000 American men will be diagnosed with prostate cancer this year, and nearly 27,000 will die of the disease. While prostate cancer is one of the most common cancers among American men, it also is very manageable, and often curable.
Providence Cancer Institute experts now have state-of-the-art technology that brings the promise of cure to more men with prostate cancer.
Phase 1 studies are the springboard for advancing new cancer treatments. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies through our own investigator-sponsored trials, and through collaborations with partners across the country.
Researchers at the Earle A. Chiles Research Institute, or EACRI, and Agonox, Inc. have published groundbreaking work concerning tumor-killing T cells which could greatly improve the immune response in cancer patients – leading to successful treatment of tumors.
Providence Cancer Institute is one of the few specialized centers in the world offering clinical trials of adoptive T-cell immunotherapy